Micromedic announces approval to conduct an extended clinical study with CellDetect on prostate cancer diagnosis

Micromedic Announces Approval from Kaplan Medical Center's Ethical Committee to Conduct an Extended Study for Diagnosis of Prostate Cancer using its CellDetect Technology

Following the promising results of a feasibility study showing the capability of CellDetect® to accurately detect prostate cancer cells in urine specimens, Micromedic announced today that it has received the approval from the Ethical Committee of the Kaplan Medical Center to conduct an extended clinical trial. This study will include about 100 samples from both prostate cancer patients and healthy controls and is expected to be completed by the thrid quarter of 2017.

Link to complete article

More News/Information
© Micromedic Technologies Ltd. site mapcontact
Site by Site2goal | Design Studio Michal Lehavi